Articles Tagged With:
-
Pediatric Genitourinary Trauma
Although genitourinary trauma is uncommon, it can have devastating consequences, both physical and psychological. Clinicians need to be prepared with the knowledge needed to optimize the outcome for each child with trauma to this very sensitive area.
-
Lenacapavir Injection and Tablets (Yeztugo)
The U.S. Food and Drug Administration has approved lenacapavir, a potent, first-in-class, capsid inhibitor, for reducing the risk of sexually acquired human immunodeficiency virus type 1.
-
Does Lipoprotein(a) Improve the Risk Calculation of the PREVENT Equation?
A pooled cohort from the Multi-Ethnic Study of Atherosclerosis and the United Kingdom Biobank study has shown that, overall, the American Heart Association PREVENT risk scores performed well at predicting atherosclerotic cardiovascular disease risk even in those with high lipoprotein(a) levels, but considering lipoprotein(a) in those with low PREVENT scores may help make therapeutic decisions in these individuals.
-
Updated Recommendations for Drug-Susceptible and Drug-Resistant Tuberculosis
The authors provide an update of recommendations for the treatment of tuberculosis, including cases with drug resistance. The recommendations include the use of newer drugs that have undergone clinical trials and shorter durations of therapy.
-
Restricting Remdesivir in an Immune Era: No Harm, Big Savings
A quasi-experimental, eight-hospital, pre-post restriction of remdesivir to only symptomatic, oxygen-requiring, immunocompromised adults during July 2023 to June 2024 led to a 90% reduction in remdesivir use (37.7% to 4.1%) without any increase in 14- or 28-day all-cause mortality, 30-day readmission, or hospital length of stay. Medium- and high-risk covariate models confirmed no mortality signal, while an intriguing rise in intensive care unit admission and mechanical ventilation use among the few post-intervention recipients was most consistent with residual confounding and confounding by indication (i.e., the sickest patients being channeled to receive therapy). In an era of widespread hybrid immunity from Omicron-descended variants, broad remdesivir formulary restriction can be implemented safely and can yield substantial cost savings without compromising outcomes.
-
Benefits of Nudging in Severe Aortic Stenosis
A single health system study of electronic provider notifications when severe aortic stenosis was discovered on echocardiography showed that referrals for aortic valve replacement significantly increased, especially in women and those > 80 years of age.
-
Movement Disorder Emergencies: Serotonin Syndrome and Neuroleptic Malignant Syndrome
Serotonin syndrome and neuroleptic malignant syndrome are both potentially life-threatening conditions caused by medications. They present with altered mental status, autonomic dysfunction, and neuromuscular abnormalities. Despite overlapping features, they differ in etiology, pathophysiology, clinical presentation, and treatment.
-
Can Vitamin D Supplementation Slow Cellular Aging?
In a large randomized, double-blind, placebo-controlled trial, vitamin D3 supplementation modestly but significantly slowed the rate of leukocyte telomere shortening over four years.
-
Blood GFAP Measurements for Rapid Diagnosis of ICH
The early diagnosis of spontaneous intracerebral hemorrhage (ICH) is important to initiate rapid interventions, such as lowering blood pressure and reversing the effects of antithrombotic medications. Plasma assays of glial fibrillary acidic protein may become a useful tool for the prehospital diagnosis of ICH, but it needs further study before adoption in the clinical setting.
-
Tolebrutinib May Slow Disability Progression in Patients with SPMS
A recent prospective study showed that tolebrutinib slows disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS). There were some safety concerns, especially hepatotoxicity. A lack of demonstrated effect on some functional outcomes warrants careful consideration and continuing study.